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Throughout many parts of the world, biomedical research 
ethics is based on a core body of well-established norms, 
rules, and principles, including the Declaration of Helsinki, 
the Nuremberg Code, the Belmont Report, and the Interna-
tional Ethical Guidelines for Biomedical Research Involving 
Human Subjects (1). The overarching goal of these codifi-
cations is to protect people against harms arising from re-
search, and from researchers experimenting on them with-
out their knowledge and permission.
More recently, and because of the increasing technological 
capabilities for digital data production, storage, and anal-
ysis (such as web and ubiquitous computing, wearables, 
apps), new opportunities for conducting biomedical re-
search have emerged. Data-intensive approaches in bio-
medicine, made possible by the increasing availability of 
digital health data and biobanks, are profoundly changing 
the ways in which research is conducted, and the role of 
research participants and health care (2-4). Physical con-
tact between researchers and study participants is no lon-
ger needed and, once collected and stored, participants’ 
data remain available for potential reuse in further research 
for various purposes. With the growth of data-intensive ap-
proaches in biomedical research, a rich discussion on the 
saliency of moral considerations pertaining to the manage-
ment of personal data in health databases and biobanks 
has unfolded (5).
THE WORLD MEDICAL ASSOCIATION (WMA) DRAFT 
ON ETHICAL CONSIDERATIONS REGARDING HEALTH 
DATABASES AND BIOBANKS
Many regional, national, and international institutions that 
make policy on biomedical research ethics recognize this 
development. Some are revising their position on the eth-
ics of data-driven biomedical research to keep pace with 
these transformative developments. In March 2015, for 
example, the WMA opened a public consultation on their 
“Draft on ethical considerations regarding health databases 
and biobanks.” The Declaration was available for public con-
sultation until June 2015 (http://www.wma.net/en/20activi
ties/10ethics/15hdpublicconsult/). It is now undergoing re-
vision by a WMA working group in light of the public com-
ments received. A definitive version is expected in 2016.
The WMA’s three-page draft Declaration is intended to 
complement the Declaration of Helsinki by providing 
“additional principles for the ethical use of data in Health 
Databases and human biological material in Biobanks” 
(Article 2). The Declaration defines “health databases” as 
systems for collecting, organizing, and storing health infor-
mation, which enable the information to subsequently be 
retrieved in a structured manner; and “biobanks” as collec-
tions of biological material and associated data from differ-
ent individuals (Article 3).
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TABLE 1. Shifts in the collection and use of health data and their implications for biomedical research
Shift What is the challenge?
Changing concept of “personal data” Personal data are personal for a wider range of people than the individual from which they were 
collected or otherwise processed.
Limits of anonymization Data are never fully anonymized in the sense that the re-identification individuals becomes 
impossible. New opportunities for data linkage and the integration of different data sets can make 
re-identification possible. Further, anonymization may not be the best means to protect and 
promote the interests of both researchers and participants.
Added pressures on consent 
procedures
When data are collected and stored for future use, it is impossible to anticipate all future uses and 
thus require fully informed and specific consent.
Transferability of health data to other 
domains (and vice versa)
Virtually any data set can be used to make health-relevant inferences pertaining to individu-
als (especially in the context of predictive analytics). Thus, also data that were not collected for 
health-relevant purposes can be used in a health-relevant way.
Risks associated with predictive 
analytics
It is very difficult, if not impossible, for individuals to know what data are used to make inferences 
and predictions about them. If data are used to harm them, or if inaccurate data are used, there 
are typically few options to rectify the harm/error or seek redress.
The Declaration is divided into three parts: a Preamble (Ar-
ticles 1-12), a section on relevant ethical principles (Articles 
13-22), and a section on governance (Articles 23-27). After 
defining “health databases” and “biobanks” as well as speci-
fying their potential to accelerate biomedical research, the 
Declaration declares its remit to include “the use of health 
information beyond the individual care of patients” (Article 
4). This means that health information used for research 
purposes is within the remit of the Declaration. Not in-
cluded within its remit, however, are health databases and 
biobanks containing “fully anonymized or non-identifiable 
data” (Article 8).
The ethical principles that underpin research ethics policies 
typically seek to protect and enhance participants’ rights to 
privacy, confidentiality, and self-determination with respect 
to the disclosure of their information for research purpos-
es. The draft Declaration indeed stresses the importance of 
respecting these rights, manifested, as it is commonly the 
case, in the duty to obtain the participant’s consent to have 
their identifiable information included in a health database 
or their biological material deposited in a biobank. Condi-
tions that make informed consent possible on the side of 
the patient or participant include the need to receive clear 
details on the research modalities (eg, how participant’s 
data will be used, for what purpose, what privacy arrange-
ments are in place) (Article 15). The WMA Draft Declaration 
also mentions participants’ right to request the correction 
of mistakes or omissions to their data (Article 16) and the 
right to withdraw consent for their identifiable information 
to remain included in a health database and their biologi-
cal material to remain in a biobank (Article 17). These rights 
bear clear resonance with the recent data protection regu-
lation reform in the European Union (6).
The WMA’s draft Declaration also considers the practices of 
blanket and open consent as ethically unacceptable. Con-
ditional broad consent (Article 18) (ie, consent to future 
research studies), in contrast, is deemed ethically accept-
able provided that: “during the consent process, all prin-
ciple information about future use is provided, all relevant 
safeguards are secured, the use of health data or biological 
material is transparent, and if all use is explicitly approved 
by a research ethics committee.”
The draft Declaration calls for a “dedicated independent 
ethics committee” to approve the establishment of health 
databases and biobanks (Article 20) as well as to approve 
all use of data and human material and decide on the 
type of consent necessary, taking into consideration risks 
and benefits of the activity. As far as governance is con-
cerned, it requires appropriate management and safe-
guards. For instance, adequate governance arrangements 
should be made concerning the purpose of the health 
database or biobank, the modalities of collection and ac-
cess, the process to obtain consent, the length of time for 
storage, and the responsible individuals for governance 
and procedures for addressing enquires and complaints 
(Article 26).
Such is the brief background. While we support the codi-
fication of ethical principles for use of data in health data-
bases and human biological material in biobanks, particu-
larly given the pervasive use of digital health data, we find 
that the remit of the draft Declaration is unduly narrow and 
fails to offer meaningful advancement of the ethical prin-
ciples stated in the Declaration of Helsinki. Changing prac-
tices in the collection and use of digital data require a re-
vised framework and nomenclature regarding the norms, 
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rules, and principles governing biomedical research. In the 
remainder of this article, we discuss five areas that ought 
to be taken into consideration in this process. These areas 
relate to shifts in health data-centric biomedical research 
that are relevant for governance and regulation (Table 1). 
Although our discussion takes the draft WMA Declaration 
as a reference point, our argument is applicable to the 
regulation of the collection and use of health data more 
broadly. By doing so, we also seek to contribute to scholar-
ship on “knowledge landscapes,” a concept that acts as an 
analytical tool to map and scrutinize the heterogeneous 
sources, flows, and uses of e-health systems (7). We be-
lieve that such an integrated approach that foregrounds 
how knowledge landscapes are used and navigated when 
scrutinizing its ethical, regulatory, and social challenges, is 
much more timely and fruitful than anchoring our analysis 
in the domain in which a database is located, be it clinical, 
scientific, or commercial.
WHAT ARE PERSONAL HEALTH DATA? WHAT IS A 
HEALTH DATABASE/BIOBANK?
The draft WMA Declaration makes repeated reference to 
individual-level health data. An aspect that the draft does 
not refer to explicitly is that health data increasingly trav-
el between the clinical and non-clinical domains, and be-
yond. In the digital era, health databases can be linked with 
other types of databases, including those that do not origi-
nate in the clinic (eg, administrative and commercial data-
bases), in order to extend the range of use of the data. In 
principle, no type and source of data are excluded from 
being used for health-related purposes (either in the clinic 
or for research) or in the commercial domain. Even web 
browsing data, the use of which is mostly unregulated, can 
offer important clues about one’s health (8,9). In this light, 
should we treat all data that can be mined for health-rele-
vant purposes at a successive stage as “health data”? What 
about the metadata that databases also include? Moreover, 
in the context of increasing portability of health informa-
tion, databases themselves might host data that were im-
ported from elsewhere; what forms of consent would then 
apply when data sets converge? At stake are the bound-
aries of what counts as “data collection” as much as what 
counts as “health data.”
Given this definitional challenge, it is important to draw 
finer distinctions between different types of biobanks 
and health databases according to their mission, practic-
es, uses, and the commercial stakes involved in them, es-
pecially along the dimensions outlined in Table 2.
PERSONAL DATA ARE PERSONAL FOR MORE THAN ONE 
PERSON
The draft WMA Declaration’s emphasis on rights (eg, to 
privacy) to the detriment of duties (eg, to communicate 
actionable findings that impact on the health of others) 
may push to the background other important moral and 
ethical concerns that arise in the context of data-rich bio-
medical research. One such concern emerges from the 
fact that “personal” and “individual” data are not synony-
mous, although they are often treated as such (10-12). 
Biological information often discloses something both 
about the person who donated the data or sample and 
biologically related (or even unrelated) others. For in-
stance, much genetic data provide information about 
more than just one individual (13). Consequently, both 
harms and benefits, and the appropriate balance and re-
lationship between rights and duties, need to be consid-
ered. In particular, the notion that rights to privacy, con-
fidentiality, and self-determination entitle an individual 
to exercise control over the use and disclosure of infor-
mation concerning her- or himself in every instance, es-
pecially in the case of genetic information, ought to be 
challenged in light of this broader understanding of the 
personal nature of data. Should an individual person have 
TABLE 2. Descriptive dimensions of biobanks and health databases
Category Questions to be asked
Content What kind of data and/or materials are stored in the database/bank?
Personal data relationships Can relevant demographic and familial relations be inferred directly from the data? (eg, genetic and ge-
nomic data sets, genealogical databases, etc.)
Intended uses of the data Is the primary intended use of the data biomedical research, or something else? Does data use aim to cre-
ate public benefits? What are the commercial stakes and interests?
Security standards What are the security standards (eg, cloud-based databases with data located at participating institutions; 
data centralized in data safe havens; access control policy)?
Actual uses of the data Who is using the data, and for what purposes?
Mode of governance Who can populate the database? Who can access data? Who decides on access? Is there transparency on 
these decisions, and on how these decisions are made?
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an unfettered “right” to control the communication of an 
actionable research finding to a genetic relative that may 
have implications for him or her?
We may also imagine that through a number of people 
each giving access to their own individual records for re-
search, or even sharing their data publicly, it may be pos-
sible to establish a probabilistic correlation of clinical rele-
vance between two characteristics A and B (eg, a biomarker 
and late onset disease). The sheer volume of data and the 
relative ease with which digital data can be mined would 
make this possible. For any individual exhibiting charac-
teristic A, the hypothesis of them also possessing or devel-
oping characteristic B could lead to tangible implications, 
even if the quality of the data and the robustness of the 
correlation were never verified. This raises the question of 
how such practices can be regulated. The European Union’s 
forthcoming General Data Protection Regulation will give 
important additional rights to data subjects that will make 
it more difficult for corporations to use data without the 
knowledge of the data subject, and will make it easier for 
people to seek redress (6). It remains to be seen, howev-
er, whether large corporations with pockets deep enough 
to tolerate pecuniary penalties will comply with the new 
rules, and how they will be enforced (14,15). Further, let us 
imagine that one of the correlated characteristics was as-
sociated to an observable (physical or behavioral) trait and 
that some linkage could subsequently be made between 
the trait and the increased likelihood of a specific condition. 
To use a well-known example, BRCA mutations increase the 
risk of breast and ovarian cancer manifold. Similarly cancer 
risk increases with consumption of processed meat or al-
cohol. It is likely that other correlations will be discovered 
in the future. The issue has been raised by scientists work-
ing on medical data analytics in a large collaborative re-
search project funded by the European Commission (16), 
in relation to the use of unsupervised learning techniques 
in medical data mining: What happens when these tech-
niques yield such correlations, warranted or not, that are 
likely to result in social discrimination – positive or negative 
– for the individuals exhibiting this particular trait?
ANONyMIzATION IS NOT FOREvER
Article 8 of the draft WMA Declaration states that health 
databases and biobanks that “exclusively contain fully an-
onymised and non-identifiable data and biological mate-
rial” are excluded from the remit of the Declaration. The no-
tion that “full anonymization” offers the best protection and 
promotion of participants’ interests needs to be reconsid-
ered. Not only is the anonymity of data and material highly 
context-dependent, but data and material that are anony-
mized today may no longer be anonymous in the context 
of tomorrow’s technologies and data resources. Whatever is 
contained in a health database or a biobank may be anony-
mized and non-identifiable at the time it is set up, but this 
may not remain so over time, especially when data from 
the database or biobank are linked with other data sets. 
The re-identifiability of the information in a database or 
biobank is relative and contingent, and therefore needs to 
be reconsidered regularly. Exemptions from research eth-
ics requirements for supposedly anonymized data gives the 
false and dangerous impression that anonymized data are 
inherently less prone to re-identification. Policies should be 
very clear about ethical concerns about data and biologi-
cal materials continuing even after anonymization, but also 
that anonymization is not a process that necessarily pro-
motes the interests of both researchers and participants 
at all times. Sophisticated information security designs at 
both the technological and organizational levels can go a 
long way in protecting participants’ identity while ensuring 
long-term consistency of the research infrastructure, but 
whether, and under what circumstances, should and could 
anonymization be reversible is a very complex terrain that 
must be explored contextually in every project.
It is also worth emphasizing yet again that the term 
“anonymous” must be distinguished from “anonymized”. 
Anonymization is a process performed on identifiable 
data or material, which makes the data or material no 
longer identifiable. This concept is categorically distinct 
from “anonymous,” which signifies a status of data or ma-
terial, namely that which never was identifiable at the 
origin. This is a crucial distinction from a data protection 
law perspective, because it means that the processing of 
personal data for the purposes of achieving anonymiza-
tion (ie, the rendering of personal data to an anonymized 
state) remains subject to data protection laws. That is, pri-
or to the completion of this process of anonymization, 
the data are still “personal” in the way that data protection 
laws define the term (17). It must be noted, however, that 
the distinction is frequently challenged in a time when 
distributed and automated data collection and record 
linking are increasingly available.
vARIETIES OF CONSENT
Informed consent is a long-standing pillar of ethical re-
search. However, emerging forms of science that focus on 
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data analytics rather than bodily intervention encourage a 
rebalancing of personal autonomy and societal interests. 
It can be the case that other forms of consent may ren-
der research ethical in databased biomedical science. The 
“classic” form of specific consent (ie, consent to a specific 
study) must be contrasted with non-specific consent. The 
latter includes open, broad, and blanket consent, on which 
a vast literature has emerged (18-21). “Open” consent is 
“consent to unrestricted redisclosure of data originating 
from a confidential relationship, namely (...) health records, 
and to unrestricted disclosure of information that emerges 
from any future research on (...) genotype-phenotype data 
set, the information content of which cannot be predicted,” 
with no promise of anonymity (22). “Blanket” consent puts 
no restriction to scope and duration of consent, whereas 
“broad” consent restricts use of personal data to broad ar-
eas of research, eg, biomedical research. In general, obtain-
ing specific informed consent need not be an absolute re-
quirement in the context of data-centric research, as forms 
of non-specific consent may be ethical even if they are not 
universally regarded as “truly informed” consent. Moreover, 
in some circumstances, anonymous or anonymized data 
that were collected for a different purpose may be used 
legally and ethically for research purposes in some juris-
dictions, including when it is not reasonably possible to 
re-contact the data donor for consent. On this basis, large 
databanks that have been constructed by aggregating and 
linking data sets collected in the context of routine and ad-
ministrative services can now support a variety of different 
kinds of research projects.
PREDICTIvE ANALyTICS, COMMERCIAL USES, PRIvATE 
PARTNERSHIPS
Personal data are increasingly used by commercial com-
panies, notably in the context of consumer scoring. This 
creates various types of risks to individuals and groups and 
in varying orders of magnitude. They are relevant to the 
governance of biobanks and data sets as the ownership of 
data and samples stored in a biobank can change and give 
rise to uses of data that were not intended by the biobank’s 
initial mission. The issue of funding of health databases and 
biobanks, and the related concern of sustainability, ie, what 
happens upon the termination or winding down of a da-
tabase or biobank, are of crucial importance in this respect 
(23). It must furthermore be noted that the boundaries 
between health care, commercial, and research purposes 
are increasingly blurred. This is evidenced, for example, by 
the fact that a private company selling personal genomics 
services (23andMe) received NIH funding to build survey 
tools, expand its gene database, and use its stores of ge-
netic data for research projects (24,25). Another example is 
that a philanthropic foundation established a $20 million 
endowment at Harvard Business School “to find ways to 
accelerate breakthroughs and advance commercialization 
of precision medicine by harnessing the energy and ideas 
of the medical, science and entrepreneurial communities 
in the city” (26). More easily than ever before, data gener-
ated for one kind of purpose and services (eg, marketing) 
can be repurposed for other kinds of projects and services 
(eg, health and social care).
In the everyday operation of a health data project, there are 
governance issues associated with the need to provide up-
to-date and relevant information as these projects develop 
and ramify through partnerships. Digital technologies can 
offer relatively inexpensive opportunities for transparent 
and inclusive communication, but solutions will have to 
be contextual to the project.
DISCUSSION
The ethical guidelines for health databases and biobanks 
outlined in the WMA’s draft Declaration define not only 
rights of participants, but also what counts as data gath-
ering, linking and handling, scientific research, and even 
medical practice. As such, the draft Declaration does not 
simply specify the conditions that need to be met for re-
search to be considered ethical, but it also creates ex-
pectations, imagines valuable futures, and defines what 
desirable and undesirable scenarios would be. Although 
the Declaration of Helsinki was conceived as a deonto-
logical professional code for physicians, these stakehold-
ers should welcome the opportunity to expand ethical 
reflections to new issues arising in biomedical research, 
namely that of digital health data. The challenge ahead 
is not so much that of extending existing ethical princi-
ples and reflecting on how they play out in a changing 
landscape of data collection and use. Instead, along with 
methodological changes, the management of health da-
tabases and biobanks is accompanied by changes in the 
social, economic, and moral order, which require a new 
language in which we frame and address the ethical chal-
lenges arising. The concept of “knowledge landscapes” 
would be a useful tool toward this goal, as it enables us 
to identify interrelated areas of information, knowledge, 
and associated narratives and practices, rather than con-
straining our analysis by existing nomenclatures and cat-
egories that separate traditional “types” of databases and 
domains of use (7).
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CONCLUSIONS
On the basis of the broader approach to the analysis of 
knowledge production underpinned by the notion of 
“knowledge landscapes,” we have argued that digital 
health data require rethinking norms, categories, and no-
menclatures governing biomedical research. In particular, 
we have identified five shifts in the collection and use of 
digital data that are of immediate relevance to the regula-
tion of such research (Table 1).
These shifts call for a broadened ethical discussion pertain-
ing to digital health data. Ethical guidelines and policies 
need to be understood as having a socially constructive 
role in the future directions of biomedical research. The 
making of such policies is an act of social imagination that 
encompasses the full array of actors in the biomedical re-
search ecosystem: health professionals, regulators, partici-
pants, and publics. As we are all affected, we are all encour-
aged to deliberate on the ethical issues at play.
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